Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 25.72M P/E - EPS this Y 52.50% Ern Qtrly Grth -
Income -16.35M Forward P/E -2.89 EPS next Y 61.70% 50D Avg Chg 6.00%
Sales -2.85M PEG - EPS past 5Y - 200D Avg Chg -21.00%
Dividend N/A Price/Book 0.80 EPS next 5Y - 52W High Chg -65.00%
Recommedations 1.00 Quick Ratio 8.39 Shares Outstanding 5.32M 52W Low Chg 50.00%
Insider Own 3.03% ROA -37.02% Shares Float 5.16M Beta 1.02
Inst Own 9.17% ROE -58.40% Shares Shorted/Prior 123.62K/131.01K Price 4.94
Gross Margin - Profit Margin - Avg. Volume 176,457 Target Price 33.00
Oper. Margin -1,199.58% Earnings Date May 9 Volume 25,034 Change -0.60%
About Lipocine Inc.

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

Lipocine Inc. News
03/25/24 Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
03/07/24 Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
03/06/24 Lipocine to Present at 36th Annual Roth Conference
02/06/24 Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
02/02/24 Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
01/18/24 Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
12/19/23 Lipocine to Present at Biotech Showcase 2024
11/13/23 Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023
11/08/23 Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023
11/01/23 Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023
10/26/23 Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression
10/23/23 Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference
09/19/23 Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference
08/16/23 LPCN: Trial Results Improve Outlook
08/10/23 Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023
07/31/23 LPCN: 1148 Shows Muscle Loss Reversal
07/27/23 LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis
06/14/23 Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference
06/07/23 Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023
05/19/23 LPCN: 1154 Results Illuminate Accelerated Pathway
LPCN Chatroom

User Image whateverhappens Posted - 21 minutes ago

$LPCN Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis ● Met primary and Hepatic Encephalopathy (HE) endpoints in Phase 2 study ○ Increase in Skeletal Muscle Index (SMI) observed at Week 24 was maintained through 52 weeks ○ Participants on placebo increased SMI when switched to LPCN 1148 ○ Fewer Overt Hepatic Encephalopathy (OHE) events and time to first recurrent OHE event was longer while on LPCN 1148 therapy ● LPCN 1148 was well-tolerated, with AE rates and severities similar to placebo. ○ Participants on LPCN 1148 were hospitalized for fewer days LPCN 1148 is targeted to be a “First in Class” product candidate with a novel mechanism of action (MOA). Lipocine plans to meet with the FDA to discuss a development path to NDA filing.

User Image amazingcrwns Posted - 24 minutes ago

$LPCN This is not the pre-market I was expecting when the PR came out.

User Image LMMoney Posted - 40 minutes ago

$LPCN https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318194373&type=HTML&symbol=LPCN&cdn=392f9b4722293094badd1eb074bc211c&companyName=Lipocine+Inc.&formType=8-K&dateFiled=2024-03-28

User Image ScaryAurry Posted - 14 hours ago

$LPCN I want people in here to go into the topline data release with realistic expectations. I think this release could cause a spike, but nothing substantial due to the fact that the main roadblock towards further development for the company is finding a partner for 1148 anyways. Positive results could accelerate the hunt for a partner on the drug but I think it is going to be awhile for 1148 to make it to market. 1154 seems like the most immediate catalyst that can really move this stock due to how the company has diverted its focus to CNS disorders, and that it has little red tape to go through to gain approval and make it to market. Also this stock historically has had odd reactions to news, it will not spike directly after news is dropped so swing traders sell, and then a couple days later the stock will post maturely spike. I wouldnt blame people for selling on good news and trying to buy back in post spike in anticipation for 1154 results in the end of Q2.

User Image Chrisdel Posted - 16 hours ago

$LPCN i think they will release data EOD friday to let the info soak in through the weekend.

User Image Tshanky_ Posted - 17 hours ago

$LPCN I predict there is a LPCN PR dropped at 8am ET March 28, 2024, which highlights Phase II topline data.

User Image ScaryAurry Posted - 18 hours ago

$LPCN Yikes

User Image aah98a Posted - 20 hours ago

$LPCN Which Data is expected soon? LPCN 1154 data to be released by June 30th. What's the latest on NASH?

User Image ScaryAurry Posted - 20 hours ago

$LPCN We are building momentum for the topline data release

User Image Geraldbeak Posted - 20 hours ago

$LPCN Reminder that trading, ultimately, is extremely personal. I would never try to convince someone to buy or sell and I would never rag on someone who lost money on a stock, even if they are throwing a childish tantrum. It sucks when you lose money. So, if someone is passing on the floor in her, ignore them. They're throwing a childish tantrum. Look down at them with pity.

User Image Tradesy718 Posted - 21 hours ago

$LPCN most names on my watchlist are red today, except this one

User Image NothnSpecial Posted - 1 day ago

$LPCN

User Image TomMac64 Posted - 1 day ago

$LPCN Made a mistake posting green sorry !

User Image TomMac64 Posted - 1 day ago

$LPCN And tell Amazingcrowns he’s a wimp for blocking me !

User Image Tshanky_ Posted - 1 day ago

$LPCN oh that’s what it is. You got hurt. You know bios in early stages are always beat down? But the ones that actually have pipeline, and progress start to recover. This is why I don’t suggest holding early staged bios longterm unless they start producing rev. LPCN is having a lot of success rn and 2024 is a big year for the company. Likely commercialize eoy or 2025. There are plenty of scam bios to hate on. This isn’t one

User Image TomMac64 Posted - 1 day ago

$LPCN I’ve been around this train-wreck for 4 yrs and I have plenty of info

User Image whateverhappens Posted - 1 day ago

$LPCN I guess you are allergic to making $

User Image Tshanky_ Posted - 1 day ago

$LPCN not manipulated just hardly any selling into the bid. It was actually manipulated down if anything. Where were you when this fell from 5.20 to 3.80 on literally 234,000 volume over 8 trading days? You just have no real DD, but just come here and post bearish, because it ran 20% on trading volume that is more than two times its average. You have no idea of what the company does or their pipeline. It’s a bio in the developmental stage and they will complete a pivotal trial in q2, nda in q4. You know what follows that? They also have topline phase II data dropping this week. But you’re too tunnel visioned to see opportunities

User Image TomMac64 Posted - 1 day ago

$LPCN I wouldn’t buy this nightmare if it was the last remaining stock listed on the NYSE !

User Image whateverhappens Posted - 1 day ago

$LPCN sorry you missed out on adding at 2.41 like I did.

User Image TomMac64 Posted - 1 day ago

$LPCN There were 73K shares traded today nobody is trying to get in it was totally manipulated like most tiny irrelevant bios nobody is complaining cause the manipulation was to the upside my suggestion to anyone here with profit is to sell this lemon !

User Image ScaryAurry Posted - 1 day ago

$LPCN Anyone notice patel loaded up on shares a couple weeks ago?

User Image whateverhappens Posted - 1 day ago

$LPCN I ain’t selling a single 44k shares. 1154 is compelling especially.

User Image ScaryAurry Posted - 1 day ago

$LPCN What do people think this can get to once topline data releases?

User Image ScaryAurry Posted - 1 day ago

$LPCN Looks like people are trying to get in before the topline data comes out this week, big week for this stock I loaded up today on shares.

User Image Tshanky_ Posted - 1 day ago

$IBRX $CDIO $ICU $LPCN $OSA LPCN 🔥topline data released this week. Been trying to tell y’all. All of these tickers will have their moment. OSA business update /ER call today. May get volatile either way, but hopeful for FDA approval end of April Add a couple more bios I like NRSN, and CADL IBRX getting back in a juicy spot as well

User Image chiefcoho Posted - 1 day ago

$LPCN I I I understand that UIKit Look

User Image Tshanky_ Posted - 1 day ago

$LPCN I was kinda annoyed with the dip but added a lot of cheap shares, including a small buy at 3.79 on 3/22 somehow even though it says the low was 3.88

User Image aah98a Posted - 1 day ago

$LPCN What's the latest? Any news or just a build up?

User Image Tshanky_ Posted - 1 day ago

$LPCN solid

Analyst Ratings
Cantor Fitzgerald Overweight Jul 27, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Patel Mahesh V. CEO and President CEO and President May 25 Buy 5.03 8,706 43,791 107,418 05/25/23
Patel Mahesh V. CEO and President CEO and President Mar 24 Buy 0.32 150,000 48,000 1,678,090 03/24/23
Ono Richard Dana Director Director Mar 20 Buy 0.34 4,000 1,360 14,125 03/20/23
Papapetropoulos Spyros Director Director Nov 22 Buy 0.47 21,739 10,217 21,739 11/28/22
Patel Mahesh V. CEO and President CEO and President May 16 Buy 0.7699 50,000 38,495 1,303,090 05/16/22
Higuchi John W. Director Director Jan 04 Sell 1.35 6,700 9,045 693,548 01/04/21